Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

12.1K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
12.1K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

2
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
2
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

535
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
535
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

5
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
5
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

3
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
3

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chito-oligosaccharide loaded with ACC (1-aminocyclopropane-1-carboxylate) deaminase-producing bacteria improved soil microecology and cotton growth in salinized lands.

BMC plant biology·2026
Same author

Intraoperative NIR-II fluorescence guidance for precise tumor margin assessment and maximized tissue preservation in breast surgery.

Breast cancer research : BCR·2026
Same author

Cell proliferation and differentiation during epidermis renewal.

Journal of Zhejiang University. Science. B·2026
Same author

Gut microbiota-dependent metabolism of 6-shogaol generates bioactive metabolites that mediate its anti-inflammatory effects.

Food & function·2026
Same author

Pathogen-Associated Molecular Pattern (PAMP)-Induced Peptide LcPIP1 Derived from Litchi Promotes the Resistance of Litchi Fruit against Litchi Downy Blight Caused by <i>Peronophythora litchii</i>.

Journal of agricultural and food chemistry·2026
Same author

Crosstalk between iron metabolism dysregulation and the oral microbiome in periodontitis.

Journal of oral microbiology·2026

Related Experiment Video

Updated: Jun 11, 2025

Analyzing Oxygen Consumption Rate in Primary Cultured Mouse Neonatal Cardiomyocytes Using an Extracellular Flux Analyzer
11:26

Analyzing Oxygen Consumption Rate in Primary Cultured Mouse Neonatal Cardiomyocytes Using an Extracellular Flux Analyzer

Published on: February 13, 2019

8.7K

NPLOC4 aggravates heart failure by regulating ROS and mitochondrial function.

Kaidi Ren1, Yi Luan2, Yuanyuan Sun2

  • 1Department of Pharmacy, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, PR China.

International Immunopharmacology
|September 27, 2024
PubMed
Summary

NPLOC4 protein is upregulated in heart failure (HF). Inhibiting NPLOC4 reduces cardiac hypertrophy and fibrosis, offering a potential new therapeutic strategy for HF patients.

Keywords:
ERO1αHeart failureMitochondrial functionNPLOC4β-catenin/GSK3β pathway

More Related Videos

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

7.3K
Assessing Mitochondrial Function in Sciatic Nerve by High-Resolution Respirometry
08:19

Assessing Mitochondrial Function in Sciatic Nerve by High-Resolution Respirometry

Published on: May 5, 2022

2.4K

Related Experiment Videos

Last Updated: Jun 11, 2025

Analyzing Oxygen Consumption Rate in Primary Cultured Mouse Neonatal Cardiomyocytes Using an Extracellular Flux Analyzer
11:26

Analyzing Oxygen Consumption Rate in Primary Cultured Mouse Neonatal Cardiomyocytes Using an Extracellular Flux Analyzer

Published on: February 13, 2019

8.7K
In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

7.3K
Assessing Mitochondrial Function in Sciatic Nerve by High-Resolution Respirometry
08:19

Assessing Mitochondrial Function in Sciatic Nerve by High-Resolution Respirometry

Published on: May 5, 2022

2.4K

Area of Science:

  • Cardiovascular Biology
  • Molecular Medicine
  • Cellular Biology

Background:

  • Heart failure (HF) is a significant global health burden, driving the urgent need for novel therapeutic targets.
  • NPLOC4, an endoplasmic reticulum protein, is implicated in protein degradation and cellular stress responses.

Purpose of the Study:

  • To investigate the role of NPLOC4 in the pathogenesis of heart failure.
  • To evaluate NPLOC4 as a potential therapeutic target for HF.

Main Methods:

  • Utilized a transverse aortic constriction (TAC) mouse model and Angiotensin II (Ang II)-induced H9c2 cardiomyocyte model.
  • Performed transcriptomic analysis, NPLOC4 knockdown experiments, and STRING interaction analysis.
  • Assessed cardiac hypertrophy, fibrosis, reactive oxygen species (ROS) levels, mitochondrial function, and protein interactions.

Main Results:

  • NPLOC4 was found to be upregulated in HF models.
  • NPLOC4 knockdown attenuated HF progression, reducing cardiac hypertrophy, fibrosis, and ROS levels.
  • NPLOC4 depletion enhanced mitochondrial function, modulated the β-catenin/GSK3β pathway, and promoted mitophagy.

Conclusions:

  • NPLOC4 plays a critical role in HF development and progression.
  • Targeting NPLOC4 presents a promising therapeutic strategy for managing heart failure.